Filter

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 55 items for :

  • bronchopulmonary neuroendocrine tumors x
  • Refine by access: All content x
Clear All
Zhihong Chen Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701

Search for other papers by Zhihong Chen in
Google Scholar
PubMed Close
,
Lora W Forman Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701

Search for other papers by Lora W Forman in
Google Scholar
PubMed Close
,
Kenneth A Miller Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701

Search for other papers by Kenneth A Miller in
Google Scholar
PubMed Close
,
Brandon English Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701

Search for other papers by Brandon English in
Google Scholar
PubMed Close
,
Asami Takashima Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701

Search for other papers by Asami Takashima in
Google Scholar
PubMed Close
,
Regine A Bohacek Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701

Search for other papers by Regine A Bohacek in
Google Scholar
PubMed Close
,
Robert M Williams Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701

Search for other papers by Robert M Williams in
Google Scholar
PubMed Close
, and
Douglas V Faller Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701
Cancer Center, Departments of Medicine, Department of Chemistry, Boston De Novo Design, K-701

Search for other papers by Douglas V Faller in
Google Scholar
PubMed Close

-specific susceptibility, designated ‘Ras-mediated apoptosis’, can be exploited as a targeted cancer therapeutic. Bronchopulmonary, gastrointestinal, and pancreatic neuroendocrine tumors are rare tumors originating from neuroendocrine tissues ( Oberg 1999 ). Clinical

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-10-0224
Volume/Issue:
Volume 18: Issue 6
Free access
Atsuko Kasajima Department of Pathology, Technical University Munich, Munich, Germany
Member of the German Cancer Consortium (DKTK), Germany

Search for other papers by Atsuko Kasajima in
Google Scholar
PubMed Close
and
Günter Klöppel Department of Pathology, Technical University Munich, Munich, Germany

Search for other papers by Günter Klöppel in
Google Scholar
PubMed Close

they almost never metastasize to the liver. Table 4 Functioning disease associated bronchopulmonary and gastroenteropancreatic neuroendocrine tumors (BP-NETs and GEP-NETs). Syndrome Prevalence (%) and type Hormone BP

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-20-0122
Volume/Issue:
Volume 27: Issue 11
Free access
Lena Weindl Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Search for other papers by Lena Weindl in
Google Scholar
PubMed Close
,
Imke Atreya Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Search for other papers by Imke Atreya in
Google Scholar
PubMed Close
,
Peter Dietrich Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Institute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Search for other papers by Peter Dietrich in
Google Scholar
PubMed Close
,
Sabine Neubeck Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Search for other papers by Sabine Neubeck in
Google Scholar
PubMed Close
,
Markus F Neurath Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Deutsches Zentrum Immuntherapie DZI, Erlangen, Germany
Comprehensive Cancer Center CCC-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Search for other papers by Markus F Neurath in
Google Scholar
PubMed Close
, and
Marianne Pavel Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Deutsches Zentrum Immuntherapie DZI, Erlangen, Germany
Comprehensive Cancer Center CCC-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Search for other papers by Marianne Pavel in
Google Scholar
PubMed Close

Introduction Neuroendocrine neoplasms (NENs) represent a rare and heterogeneous group of malignancies with variable tumor growth ( Pavel & Sers 2016 ). They occur with an estimated incidence of 6.98 cases/100,000 citizens ( Dasari et al

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-20-0500
Volume/Issue:
Volume 28: Issue 9
Restricted access
Elke Tatjana Aristizabal Prada Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Elke Tatjana Aristizabal Prada in
Google Scholar
PubMed Close
,
Vera Heinzle Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Vera Heinzle in
Google Scholar
PubMed Close
,
Thomas Knösel Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Institute of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Thomas Knösel in
Google Scholar
PubMed Close
,
Svenja Nölting Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Svenja Nölting in
Google Scholar
PubMed Close
,
Gerald Spöttl Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Gerald Spöttl in
Google Scholar
PubMed Close
,
Julian Maurer Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Julian Maurer in
Google Scholar
PubMed Close
,
Christine Spitzweg Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Christine Spitzweg in
Google Scholar
PubMed Close
,
Martin Angele Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Martin Angele in
Google Scholar
PubMed Close
,
Nina Schmidt Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Nina Schmidt in
Google Scholar
PubMed Close
,
Felix Beuschlein Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland

Search for other papers by Felix Beuschlein in
Google Scholar
PubMed Close
,
Günter K Stalla Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany

Search for other papers by Günter K Stalla in
Google Scholar
PubMed Close
,
Rainer Blaser Institute of Medical Statistics and Epidemiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

Search for other papers by Rainer Blaser in
Google Scholar
PubMed Close
,
Klaus A Kuhn Institute of Medical Statistics and Epidemiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

Search for other papers by Klaus A Kuhn in
Google Scholar
PubMed Close
, and
Christoph J Auernhammer Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Munich, Germany
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany

Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed Close

experiments. Human bronchopulmonary neuroendocrine NCI-H727 tumor cells (p11 – p23 for main experiments) ( Cakir & Grossman 2011 ) (acquired from ATCC) and human midgut carcinoid GOT1 cells ( Kolby et al . 2001 ) (kindly provided by Prof. O Nilsson

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-17-0201
Volume/Issue:
Volume 25: Issue 5
Free access
Lisa Bodei Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
LuGenIum Consortium for Independent Research, Milan, Rotterdam, Bad Berka, London

Search for other papers by Lisa Bodei in
Google Scholar
PubMed Close
,
Irvin M Modlin LuGenIum Consortium for Independent Research, Milan, Rotterdam, Bad Berka, London
Emeritus Professor Gastroenterological Surgery, Yale University, School of Medicine, New Haven, Connecticut, USA

Search for other papers by Irvin M Modlin in
Google Scholar
PubMed Close
,
Markus Luster Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany

Search for other papers by Markus Luster in
Google Scholar
PubMed Close
,
Flavio Forrer Nuclear Medicine, Cantonal Hospital, St. Gallen, Switzerland

Search for other papers by Flavio Forrer in
Google Scholar
PubMed Close
,
Marta Cremonesi Division of Health Physics, European Institute of Oncology, Milan, Italy

Search for other papers by Marta Cremonesi in
Google Scholar
PubMed Close
,
Rodney J Hicks Centre for Cancer Imaging, The Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne, Australia

Search for other papers by Rodney J Hicks in
Google Scholar
PubMed Close
,
Samer Ezziddin Department of Nuclear Medicine, Saarland University Hospital, Homburg, Saarland, Germany

Search for other papers by Samer Ezziddin in
Google Scholar
PubMed Close
,
Mark Kidd Wren Laboratories, Branford, Connecticut, USA

Search for other papers by Mark Kidd in
Google Scholar
PubMed Close
, and
Arturo Chiti Humanitas University, Milan, Italy

Search for other papers by Arturo Chiti in
Google Scholar
PubMed Close

Introduction It is now widely accepted that peptide receptor radionuclide therapy (PRRT) is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic (GEP) or

Article Type:
Article Commentary
DOI:
https://doi.org/10.1530/ERC-16-0258
Volume/Issue:
Volume 23: Issue 8
Free access
Judith A Gilbert Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Judith A Gilbert in
Google Scholar
PubMed Close
,
Laura J Adhikari Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Laura J Adhikari in
Google Scholar
PubMed Close
,
Ricardo V Lloyd Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Ricardo V Lloyd in
Google Scholar
PubMed Close
,
Joseph Rubin Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Joseph Rubin in
Google Scholar
PubMed Close
,
Paul Haluska Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Paul Haluska in
Google Scholar
PubMed Close
,
Joan M Carboni Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Joan M Carboni in
Google Scholar
PubMed Close
,
Marco M Gottardis Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Marco M Gottardis in
Google Scholar
PubMed Close
, and
Matthew M Ames Department of Molecular Pharmacology and Experimental Therapeutics, Department of Laboratory Medicine and Pathology, Department of Oncology, Oncology Drug Discovery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA

Search for other papers by Matthew M Ames in
Google Scholar
PubMed Close

IGF1R and Hsp90 for development of novel anticancer drugs for, at a minimum, bronchopulmonary neuroendocrine tumors. Supplementary data This is linked to the online version of the paper at http://dx.doi.org/10.1677/ERC-09-0318 . Declaration of

Article Type:
Research Article
DOI:
https://doi.org/10.1677/ERC-09-0318
Volume/Issue:
Volume 17: Issue 3
Free access
E Baudin Endocrine Oncology Unit, Imaging Department, Gustave Roussy, Villejuif, France

Search for other papers by E Baudin in
Google Scholar
PubMed Close
,
J Capdevila Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), IOB Quirón-Teknon, Barcelona, Spain

Search for other papers by J Capdevila in
Google Scholar
PubMed Close
,
D Hörsch ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Bad Berka, Germany

Search for other papers by D Hörsch in
Google Scholar
PubMed Close
,
S Singh Division of Medical Oncology, University of Toronto, Sunnybrook Odette Cancer Center, Sunnybrook HSC, Toronto, Ontario, Canada

Search for other papers by S Singh in
Google Scholar
PubMed Close
,
M E Caplin Neuroendocrine Tumour Unit, Royal Free Hospital School of Medicine, London, UK

Search for other papers by M E Caplin in
Google Scholar
PubMed Close
,
E M Wolin Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Search for other papers by E M Wolin in
Google Scholar
PubMed Close
,
W Buikhuisen Department of Thorax Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands

Search for other papers by W Buikhuisen in
Google Scholar
PubMed Close
,
M Raderer Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Search for other papers by M Raderer in
Google Scholar
PubMed Close
,
E Dansin Thoracic Oncology Unit, Centre Oscar Lambret, Lille, France

Search for other papers by E Dansin in
Google Scholar
PubMed Close
,
C Grohe Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin, Germany

Search for other papers by C Grohe in
Google Scholar
PubMed Close
,
D Ferone Neuroendocrine Tumour Unit, Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy

Search for other papers by D Ferone in
Google Scholar
PubMed Close
,
A Houchard Data and Insights Generation and Strategy, Ipsen, Boulogne-Billancourt, France

Search for other papers by A Houchard in
Google Scholar
PubMed Close
,
X-M Truong-Thanh Medical Affairs, Ipsen, Boulogne-Billancourt, France

Search for other papers by X-M Truong-Thanh in
Google Scholar
PubMed Close
,
D Reidy-Lagunes Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, New York, USA

Search for other papers by D Reidy-Lagunes in
Google Scholar
PubMed Close
, and
the SPINET Study Group
Search for other papers by the SPINET Study Group in
Google Scholar
PubMed Close
the SPINET Study Group

Introduction Bronchopulmonary (BP) neuroendocrine tumors (NETs; typical carcinoids and atypical carcinoids (TCs and ACs)) account for 20–25% of NETs and 1–2% of lung malignancies ( Öberg et al. 2012 , Filosso et al. 2018 , Baudin et al

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-23-0337
Volume/Issue:
Volume 31: Issue 9
Open access
Guido Rindi Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Università Cattolica del Sacro Cuore, Rome, Italy
ENETS Center of Excellence, Neuroendocrine Tumour (NET) Center, Rome, Italy

Search for other papers by Guido Rindi in
Google Scholar
PubMed Close
and
Frediano Inzani Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
ENETS Center of Excellence, Neuroendocrine Tumour (NET) Center, Rome, Italy

Search for other papers by Frediano Inzani in
Google Scholar
PubMed Close

based on the common expression of the general markers of neuroendocrine differentiation chromogranin A and synaptophysin. NEN definition embraces the two families (classes) of the well-differentiated lesions, defined as neuroendocrine tumor (NET), and

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-20-0036
Volume/Issue:
Volume 27: Issue 6
Free access
Jennifer A Chan
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed Close
,
David P Ryan Department of Medical Oncology, Department of Hematology/Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA

Search for other papers by David P Ryan in
Google Scholar
PubMed Close
,
Andrew X Zhu Department of Medical Oncology, Department of Hematology/Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA

Search for other papers by Andrew X Zhu in
Google Scholar
PubMed Close
,
Thomas A Abrams
Search for other papers by Thomas A Abrams in
Google Scholar
PubMed Close
,
Brian M Wolpin
Search for other papers by Brian M Wolpin in
Google Scholar
PubMed Close
,
Paige Malinowski
Search for other papers by Paige Malinowski in
Google Scholar
PubMed Close
,
Eileen M Regan
Search for other papers by Eileen M Regan in
Google Scholar
PubMed Close
,
Charles S Fuchs
Search for other papers by Charles S Fuchs in
Google Scholar
PubMed Close
, and
Matthew H Kulke
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed Close

Drozdov I Joseph R Pfragner R Culler M Modlin I 2008 Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines . Cancer 113 690 – 700 . ( doi

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-11-0382
Volume/Issue:
Volume 19: Issue 5
Free access
Aura D Herrera-Martínez Division of Endocrinology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain

Search for other papers by Aura D Herrera-Martínez in
Google Scholar
PubMed Close
,
Leo J Hofland Division of Endocrinology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

Search for other papers by Leo J Hofland in
Google Scholar
PubMed Close
,
María A Gálvez Moreno Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain

Search for other papers by María A Gálvez Moreno in
Google Scholar
PubMed Close
,
Justo P Castaño Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain

Search for other papers by Justo P Castaño in
Google Scholar
PubMed Close
,
Wouter W de Herder Division of Endocrinology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

Search for other papers by Wouter W de Herder in
Google Scholar
PubMed Close
, and
Richard A Feelders Division of Endocrinology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

Search for other papers by Richard A Feelders in
Google Scholar
PubMed Close

original articles, were included. The following search terms, alone or in combination, were used: ‘biomarkers’, ‘novel markers’, ‘neuroendocrine tumors’, ‘NETs’, ‘neuroendocrine neoplasms’, ‘NENs’, ‘circulating markers’, ‘tissue markers’, ‘therapeutic

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-18-0354
Volume/Issue:
Volume 26: Issue 3
Free access